Lenhard R E, Prentice R L, Owens A H, Bakemeier R, Horton J H, Shnider B I, Stolbach L, Berard C W, Carbone P P
Cancer. 1976 Sep;38(3):1052-9. doi: 10.1002/1097-0142(197609)38:3<1052::aid-cncr2820380303>3.0.co;2-t.
The Eastern Cooperative Oncology Group has studied 113 patients with generalized progressive malignant lymphomas in a randomized clinical trial. Pathologic diagnosis was subclassified by cell type and nodal pattern by The Pathology Panel for Lymphome Clinical Trials. Patients were randomly assigned treatment with either cyclophosphamide (C), vincristine (O), and prednisone (P) (COP) or CO without prednisone. Initial treatment was given for 8 weeks and further randomization of responders to observation or additional chemotherapy was carried out. A significant difference in complete remission rate between treatments was shown: with COP, 43%, and with CO, 17%, indicating an important role for prednisone in inducing CR. COP was also associated with longer remission durations and improved survival. Complete remission following initial chemotherapy is also associated with longer duration of disease-free time and survival. The initial pathologic cell types and nodal pattern also strongly influence survival. Extended "maintainence" CO treatment improved disease-free remission duration, but not survival.
东部肿瘤协作组在一项随机临床试验中研究了113例广泛性进展性恶性淋巴瘤患者。病理诊断由淋巴瘤临床试验病理小组根据细胞类型和淋巴结模式进行亚分类。患者被随机分配接受环磷酰胺（C）、长春新碱（O）和泼尼松（P）（COP）治疗或不含泼尼松的CO治疗。初始治疗为期8周，对缓解者进一步随机分为观察或接受额外化疗。结果显示，两种治疗方案的完全缓解率存在显著差异：COP方案为43%，CO方案为17%，表明泼尼松在诱导完全缓解中起重要作用。COP方案还与更长的缓解期和更好的生存率相关。初始化疗后的完全缓解也与更长的无病生存期和生存率相关。初始病理细胞类型和淋巴结模式也强烈影响生存率。延长的“维持”CO治疗可改善无病缓解期，但不能提高生存率。
